Ask a room of medics why QuikClot Combat Gauze is the CoTCCC-recommended hemostatic dressing of choice, and you will get a version of the same answer. It won. It was tested against everything else and it came out on top. Chitosan is fine, but Combat Gauze is what the Department of Defense picked, and the Department of Defense picked it for a reason.

That answer is wrong. Not slightly wrong — wrong about the entire nature of the decision.

We went back to the primary record: the Committee on Tactical Combat Casualty Care meeting minutes, the guideline change document that formalized the recommendation, the Army safety study that reshaped the field, and the official TCCC instructor materials that are still taught today. What emerges is a decision that was made carefully, defensibly, and for real reasons — none of which were that Combat Gauze outperformed its competitors.

January 2008: two laboratories, two models, two different answers

The Department of Defense did not run one test. It ran two, at two separate laboratories, using two different swine hemorrhage models. Both reported to the CoTCCC at its January 2008 meeting, and the minutes of that meeting are public.

The Naval Medical Research Center used a swine femoral transection model and a four millimeter arterial punch, with a two minute free-bleed period followed by Hextend resuscitation. The agents performing well in that laboratory were Combat Gauze, Celox, and WoundStat.

The US Army Institute of Surgical Research used a six millimeter arterial punch with a forty-five second free-bleed period, also followed by Hextend. The agents performing well in that laboratory were WoundStat, Celox, TraumaStat, and Super-QR.

Read that second list again, because it is the part nobody mentions. Combat Gauze does not appear in it. The only agent that both Department of Defense laboratories independently identified as a top performer was Celox — the chitosan product, manufactured in the United Kingdom.

One more line from those same minutes deserves attention. The Army investigator summarized the state of the science by noting that both laboratories now had data showing better hemostatic agents existed than the ones the services were currently fielding. The 2008 decision was a replacement decision. The committee was not crowning a champion. It was retiring a generation of products that had underperformed.

April 2008: the vote, and the word that hides the choice

The formal record of what happened next is the guideline change document authored by Bennett, Littlejohn, Kheirabadi, Butler, Kotwal, Dubick and Bailey. Here is how it describes the decision:

Both DoD laboratories reported that Combat Gauze, WoundStat, and Celox were consistently more effective than the previously selected first-generation hemostatic agents. Consequently, the CoTCCC voted to recommend Combat Gauze dressing as the first-line treatment for life-threatening hemorrhage. TCCC Guidelines-Change 13-05

Look carefully at the word consequently. Three agents cleared the bar. One was chosen. That sentence connects those two facts as though the second follows from the first, and it does not. An entire selection step is compressed into a single adverb — and that step was not about which product stopped bleeding better.

What the selection step actually was

The answer sits in a companion review by the same lead author, explaining why WoundStat was designated the backup rather than the primary. Combat medical personnel, it says, expressed a strong preference for a gauze-type hemostatic dressing, because granules were judged more difficult to apply under field conditions.

Now apply that preference to the candidate set as it actually existed in April 2008:

Of the three agents that cleared the efficacy bar, exactly one was a gauze. Celox Gauze did not yet exist in the American candidate set; Celox was still a granule product at that point. The end users had told the committee, in plain terms, that they wanted gauze.

So Combat Gauze was selected on delivery format.

That is a completely legitimate basis for a procurement decision, and we want to be precise about this, because the point here is not that the committee got it wrong. A dressing a medic cannot deploy one-handed, in the dark, under fire, with blood-slick gloves, is worthless no matter what its chemistry does in a laboratory. Form factor is a real clinical variable. But it is a human-factors and logistics variable, not a chemistry one — and for eighteen years it has been laundered into a claim about which molecule works better.

2010: one American product fails safety, and the other survives

Two years later, the picture narrowed further. Army investigators ran a safety evaluation of the new agents in a swine vascular injury model, and the findings were serious.

WoundStat produced severe endothelial injury and transmural vessel damage. Microscopic residue from the dressing was found in the systemic circulation, and that residue produced distal thromboembolism in the carotid arteries, the jugular vein, and small pulmonary vessels. WoundStat was recalled and removed from the TCCC guidelines.

Combat Gauze went through the same model. Kaolin particles were visible on histological examination of the injured vessel walls — but there were no signs of thrombosis. It passed.

So Combat Gauze's position consolidated. Not by beating chitosan in a head-to-head trial, but by being the last product standing after the other American entrant destroyed itself.

The line in the official curriculum that settles the argument

Here is where the structural picture becomes undeniable, and the source is not a critic of the guidelines. It is the official TCCC instructor guide for Tactical Field Care, Massive Hemorrhage, which is taught to instructors as written:

Neither ChitoGauze nor Celox Gauze have been tested in the USAISR safety model, but chitosan-based hemostatic dressings have been used in combat since 2004 with no safety issues reported. TCCC Instructor Guide — Tactical Field Care 1B

The gate that killed WoundStat and cleared Combat Gauze is a United States Army model. The chitosan gauzes were never entered into it. Their acceptance into the guidelines rests instead on more than a decade of combat use without a reported safety signal — which is real evidence, and it is the kind of evidence most products never accumulate. But it is a structurally different basis, and the distinction matters.

Two things have to be said together here, because separating them is how this gets misused.

First, not tested is not failed, and it is certainly not less safe. Instructors have been collapsing those three statements into one for over a decade, and the collapse is not supported by anything in the record.

Second, this asymmetry is self-perpetuating. The incumbent has already cleared the gate. Any challenger would have to fund and pass a test the incumbent passed in 2010, and no party in this market has a financial reason to pay for that. The gap does not close on its own, and its persistence tells you nothing about the products.

2014: chitosan is added — on the committee's own statement of parity

When the guidelines were amended to add chitosan-based gauze as alternatives, the change document described the evidence this way: there are consistent data from animal studies of severe hemorrhage that chitosan-based hemostatic gauze dressings developed for battlefield application are, at least, equally efficacious as Combat Gauze.

The committee's own document says the products are equal. The committee kept Combat Gauze as the dressing of choice anyway, and added the chitosan products as alternatives beneath it.

That is not an efficacy ranking. That is an incumbency decision with an efficacy document attached to it. The recommendation carries a Level of Evidence rating of C.

The independent literature says the same thing. A swine study comparing Combat Gauze, Combat Gauze XL, Celox Trauma Gauze, Celox Gauze and ChitoGauze in a six millimeter femoral artery punch model concluded that the novel dressings performed at least as well as the CoTCCC standard, and that the lack of clear superiority of any agent suggests hemostatic dressing technology has reached a plateau for efficacy.

The natural experiment nobody talks about

There is one more piece of evidence, and it is the one that should make you sit up.

Two sophisticated militaries. The same era. The same open literature. Opposite conclusions. And each one selected the product manufactured inside its own borders.

We are not going to tell you that proves protectionism, because it does not. Two data points is not a pattern, and there are genuine confounders — different test models, different laboratories, different acquisition regulations, different clinical advisory bodies, different product availability at different moments.

But state the burden of proof correctly. Given that the head-to-head efficacy literature shows parity, national origin is at minimum a live variable in these decisions. Anyone who wants to call it pure coincidence is the one making the claim that lacks support.

The honest case for Combat Gauze

If we stopped here, this would be an argument dressed up as an analysis. Combat Gauze has genuine, product-specific advantages that have nothing to do with historical accident, and leaving them out would be dishonest.

• It carries a radiopaque marker strip. Surgeons occasionally use these dressings off-label inside body cavities, and the marker helps locate a dressing packed into tissue. That is a real, meaningful feature, and chitosan gauzes vary on it.
• It passed the Army safety model with no thrombosis signal, in the same study that ended WoundStat. That is a cleared gate, not a marketing claim.
• It resists rebleeding under limb movement. In a forty-eight animal prolonged field care study using a modified femoral artery punch model, with rebleeding assessed after limb movement at thirty minutes and again at four hours, Combat Gauze had the lowest incidence of rebleeding — better than ChitoGauze, better than NuStat Tactical, better than plain Kerlix. That is directly relevant to tactical evacuation and prolonged field care, and it is evidence acquired long after the 2008 decision that happens to support it.
• It is fully integrated into the military supply system under its own national stock number and sits inside the standard individual first aid kit.

There is one more argument made in its favor — that Combat Gauze has the largest supporting literature. That is true. It is also circular, and you should name the circle when you hear it. Selection directs research funding toward the selected product. That funding produces literature. That literature is then cited to justify continued selection. The loop is real, and it generates volume, not superiority.

What this means at the wound

Nothing here is an argument against the guidelines. The CoTCCC recommendation is sound, the products on that list all work, and if you are carrying Combat Gauze you are carrying a dressing that has cleared more testing than almost anything else in your kit. Keep carrying it.

What is wrong is the story we tell about it. And the story matters, because it produces bad downstream reasoning — most often in the form of a medic concluding that because Celox is listed as an alternative, it must be a lesser product, or that a kit built around chitosan is somehow substandard. Neither conclusion is supported by anything in the record.

So carry an effective hemostatic gauze. Kaolin or chitosan. Then spend your energy where it actually changes outcomes: exposing the wound, packing directly onto the bleeding source rather than into the general vicinity of it, using enough material to fill the tract, and holding sustained direct pressure for a full three minutes. If a dressing fails, pull it and repack — the guideline tells you to use the same type or a different one, and it is silent on chemistry because the chemistry is not the variable that is failing you.

Primary sources

• Committee on Tactical Combat Casualty Care. Meeting Minutes, 14–16 January 2008. Joint Trauma System.
• Bennett BL, Littlejohn LF, Kheirabadi BS, Butler FK, Kotwal RS, Dubick MA, Bailey JA. Management of External Hemorrhage in Tactical Combat Casualty Care: Chitosan-Based Hemostatic Gauze Dressings — TCCC Guidelines-Change 13-05. J Spec Oper Med. 2014. PMID 25344707.
• Bennett BL, Littlejohn LF. Review of New Topical Hemostatic Dressings for Combat Casualty Care. Mil Med.
• Kheirabadi BS, et al. Safety Evaluation of New Hemostatic Agents, Smectite Granules, and Kaolin-Coated Gauze in a Vascular Injury Wound Model in Swine. J Trauma. 2010.
• Rall JM, et al. Comparison of novel hemostatic dressings with QuikClot Combat Gauze in a standardized swine model of uncontrolled hemorrhage. J Trauma Acute Care Surg. 2013. PMID 23883900.
• Littlejohn LF, Devlin JJ, Kircher SS, Lueken R, Melia MR, Johnson AS. Comparison of Celox-A, ChitoFlex, WoundStat, and Combat Gauze Hemostatic Agents Versus Standard Gauze Dressing. Acad Emerg Med. 2011;18:340–350.
• National Association of Emergency Medical Technicians. TCCC Instructor Guide, Tactical Field Care 1B — Massive Hemorrhage.
• TCCC Guidelines, 25 January 2024. Joint Trauma System.

This article is educational and does not replace the current TCCC Guidelines, your local protocol, or your medical director's direction. Every clinical claim above is sourced to the primary record. Where the record is incomplete, we said so.